Carbetocin: Evidence, Mechanism, Dosing & Legal Status

Carbetocin (Duratocin, Pabal, Lonactene) is a synthetic octapeptide analog of the nine-amino-acid hormone oxytocin, engineered to resist the rapid enzymatic degradation that limits oxytocin so that a single injection can replace oxytocin's continuous infusion.19 Unlike most peptides discussed in fitness and recovery circles, carbetocin is a genuine, regulator-approved obstetric drug in much of the world — but its evidence and its legitimate use are narrow, and its consumer-facing reputation is built mostly on a story that did not pan out. This monograph separates the proven from the failed.

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. Carbetocin is a prescription, hospital-administered obstetric drug where approved and is NOT approved in the United States. Dosing figures are reported strictly as seen in the published literature and clinical labeling for completeness — not as recommendations. Any uterotonic carries serious risks and must only be used under qualified obstetric supervision. Consult a licensed clinician before any health decision.

What is carbetocin and how does it work?

Carbetocin (C₄₅H₆₉N₁₁O₁₂S; molar mass approximately 988 g/mol) is built on the oxytocin backbone with two key modifications: replacement of the labile 1-6 disulfide bridge with a carba (thioether) bond plus N-terminal deamination, and O-methylation of tyrosine at position 2.19 These changes shield the molecule from aminopeptidase and disulfide-reductase cleavage, conferring its long duration of action.20

The receptor target is the oxytocin receptor (OXTR), a Gq-protein-coupled receptor on myometrial smooth muscle. Binding triggers phospholipase-C and inositol-phosphate signaling, raising intracellular calcium and producing rhythmic uterine contractions, increased contraction frequency, and elevated resting uterine tone — clamping uterine blood vessels to reduce postpartum blood loss.2021 Mechanistic pharmacology shows carbetocin is a functionally selective, or "biased," Gq agonist: it drives Gq signaling but, unlike oxytocin, induces receptor internalization without promoting OXTR recycling back to the membrane, and its overall biological effect is roughly half that of oxytocin despite comparable receptor affinity.18 It also binds vasopressin V1a and V2 receptors with lower affinity — the basis for its mild vasoactive and antidiuretic side effects.19

Pharmacokinetically, carbetocin has an intramuscular bioavailability of about 80 percent, onset within roughly two minutes, and an elimination half-life of about 40 minutes — roughly ten times longer than oxytocin's three to four minutes.19 The heat-stable formulation used in the WHO CHAMPION trial maintains stability for 36 months at 30 degrees Celsius and 75 percent relative humidity, removing the cold-chain requirement that degrades oxytocin in hot climates.123

What is the evidence by indication?

Carbetocin's evidence is sharply split: robust and mature for obstetric hemorrhage prevention, and negative for everything else after the Prader-Willi program failed.

The obstetric evidence is the anchor. The WHO CHAMPION trial was an international, randomized, double-blind, active-controlled non-inferiority trial in approximately 29,645 women across 23 hospitals in 10 countries, comparing a single intramuscular 100 µg dose of heat-stable carbetocin against 10 IU oxytocin after vaginal birth. For the co-primary outcome of blood loss of at least 500 mL or use of additional uterotonics, rates were 14.5 percent for carbetocin versus 14.4 percent for oxytocin — non-inferiority demonstrated (relative risk 1.01, 95% CI 0.95-1.06).12 The full protocol and outcomes are registered and described at the trial publication on NEJM. A Cochrane network meta-analysis synthesizing 196 trials and 135,559 women found carbetocin "may have some additional benefits compared with oxytocin and appears to be without an increase in side effects."34 A Bayesian meta-analysis found carbetocin reduced the need for additional uterotonics at caesarean versus oxytocin (relative risk 0.43, 95% CI 0.30-0.59), and a routes-of-administration network meta-analysis ranked IV-bolus carbetocin among the top agents.56 A nested hemoglobin substudy in 1,799 women in India found comparable effects on post-delivery hemoglobin.7

The Prader-Willi story is the cautionary counterweight. PWS features a putative central oxytocin deficiency contributing to insatiable hunger, and carbetocin's receptor selectivity was the hypothesized advantage. A Phase 2 trial in 37 adolescents showed significant improvement in parent-rated hyperphagia and compulsive behaviors — an encouraging Grade B signal.11 But the Phase 3 CARE-PWS trial in 130 patients missed its prespecified primary comparison at the 9.6 mg dose; an NDA was filed on the lower 3.2 mg dose's nominal improvements, and the FDA issued a Complete Response Letter in January 2022 citing insufficient efficacy.1214 Acadia then ran a confirmatory Phase 3, COMPASS PWS, in 175 participants, which announced on September 24, 2025 that it did not meet its primary endpoint and separated from placebo on no secondary endpoint; Acadia discontinued development.1617

What doses appear in the literature?

Reported strictly as information, not a protocol. For the approved obstetric use outside the US, the dose is a single 100 µg administration: by label (Pabal, Duratocin) given as a slow intravenous injection over about one minute after delivery of the infant at caesarean under spinal or epidural anesthesia, while CHAMPION used 100 µg intramuscularly after vaginal birth.191 It is hospital-only, prescription-only, and not for self-administration. The heat-stable formulation is room-temperature-stable and uses the same single 100 µg dose.23 Lower-dose strategies have been studied at elective caesarean to mitigate hemodynamic effects.10 The investigational intranasal route for Prader-Willi used 3.2 mg or 9.6 mg three times daily before meals — but that route and indication are unapproved and the program is discontinued.11

How safe is carbetocin?

The common adverse effects, reported in roughly 10 to 40 percent of recipients, are nausea, vomiting, abdominal pain, headache, flushing or feeling warm, sweating, tremor, pruritus, and transient cardiovascular effects such as mild hypotension and tachycardia.1920 A dedicated systematic review and meta-analysis of carbetocin's side-effect profile for PPH prevention found a generally favorable profile versus combination agents and broadly comparable to oxytocin, and in CHAMPION adverse-event rates did not differ significantly between the two drugs.91 The mechanism-linked hazards are excessive uterine stimulation leading to hypertonic or tetanic contraction — with risk of uterine rupture, placental abruption, fetal distress, or paradoxical hemorrhage — and, because of V2 cross-activity, a theoretical risk of water retention and hyponatremia with excessive dosing or large fluid loads.19

The contraindications are strict: carbetocin must not be given before delivery of the infant, must not be used to induce or augment labor, and is contraindicated in hypersensitivity to oxytocin or carbetocin, serious cardiovascular disease, epilepsy, pre-eclampsia or eclampsia, and hepatic or renal impairment, with caution in asthma and migraine.19 There is a recognized interaction with prostaglandin cervical-ripening agents such as dinoprostone and misoprostol, where concurrent use raises the risk of excessive contraction.19 No specific tumor or angiogenesis safety signal has been established for carbetocin in the obstetric literature.

What is the FDA, WHO, and WADA status in 2026?

In the United States, carbetocin is not approved for any indication; it has never been FDA-approved as an obstetric drug, and the intranasal Prader-Willi pathway ended with a 2022 Complete Response Letter and the failed 2025 Phase 3, so there is no FDA-approved carbetocin product as of 2026.1517 Internationally, it is a different picture: carbetocin was first approved in Canada in June 1997 and is now an approved obstetric drug in 80-plus countries, with the room-temperature-stable Pabal formulation approved in the EU.1923 Following CHAMPION, the WHO updated its uterotonic recommendations in 2018 to include carbetocin for PPH prevention where its cost is comparable to other effective uterotonics, and carbetocin is on the WHO Essential Medicines List.22 Its heat stability is specifically advantageous in low- and middle-income settings where oxytocin cold-chain integrity is unreliable.24

For athletes, neither oxytocin nor carbetocin is named on the WADA Prohibited List, and neither is an established performance-enhancing agent, so carbetocin is not currently a recognized doping substance — though athletes remain under strict-liability rules and should verify current status via GlobalDRO.25

Bottom line. Carbetocin is a genuinely useful, evidence-backed obstetric drug for preventing postpartum hemorrhage, where the human-RCT evidence is strong and mature (Grade A) and its decisive edge is a single-dose, heat-stable profile that survives without a cold chain — a real global-health advance endorsed by WHO. Everything beyond obstetrics is hype or failure: the intranasal Prader-Willi story did not survive rigorous Phase 3 testing, and there is no human evidence for any biohacking, mood, anti-aging, or athletic use. In the US it remains entirely unapproved, and any consumer-grade "research peptide" carbetocin is unverified, unregulated material outside the legitimate clinical supply. Regulatory facts here are current as of June 2026 and should be re-verified for later changes.